Papers/PMID:26845108
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
The Cochrane database of systematic reviews2016The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
iron(2+) — no detected effect on health-related quality of life
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“We found no evidence for a difference in quality of life with addition of iron to ESAs (standardized mean difference 0.01 (95% CI -0.10 to 0.12); P = 0.88; 1124 participants; three RCTs; high-quality evidence).”
Quoted verbatim from The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.. - Study
- meta-analysis
- Participants
- 1,124
- Population
- People with chemotherapy-induced anaemia receiving erythropoiesis-stimulating agents (ESAs) in both arms; iron added to ESA in one arm, ESA alone in the other; pooled across intravenous and oral iron
Effect 0.01 standardised mean difference, 95% CI -0.1 to 0.12
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.2016PMID:26845108Permalink